Evidence map›Paper›PMID 23040748›Full record

ReviewNeurosurgery clinics of North America2012

Management options for persistent postoperative acromegaly.

Nestoras Mathioudakis, Roberto Salvatori

Abstract readReview
In one paragraph

Review in Neurosurgery clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Approach to the Patient With Treatment-resistant Acromegaly.The Journal of clinical endocrinology and metabolism · 2022
    Article
  2. Octreotide-Resistant Acromegaly: Challenges and Solutions.Therapeutics and clinical risk management · 2020
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nestoras MathioudakisJohns Hopkins University School of Medicine, Division of Endocrinology & Metabolism, Department of Medicine, Baltimore, MD 21287, USA.
Roberto Salvatori

Funding

Interdepartmental Training Program in Cellular and Molecular EndocrinologyT32DK007751 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WOLFE, ANDREW M · 1997 to 2016
$4.6M
NIDDK NIH HHS T32 DK007751
6 · The paper itself

Abstract

This article presents management options for the patient with acromegaly after noncurative surgery. The current evidence for repeat surgery, adjuvant medical therapy with somatostatin analogues, dopamine agonists, the growth hormone receptor antagonist pegvisomant, combination medical therapy, and radiotherapy in the context of persistent postoperative disease are summarized. The relative advantages and disadvantages of each of these treatment modalities are explored, and a general treatment algorithm that integrates these modalities is proposed.

Indexed as

AcromegalyCombined Modality TherapyHuman Growth HormoneHumansPituitary NeoplasmsPostoperative PeriodHuman Growth Hormone

Identifiers

PMID23040748
PMCPMC6031123

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.